UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

Description

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.

Conditions

Alzheimer Disease

Study Overview

Study Details

Study overview

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study.

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States, 35294

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 2. Negative urine or serum B-hCG test within 2 days of \[C-11\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
  • 1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
  • 2. Inability or contraindication for undergoing MRI and/or PET imaging
  • 3. Inability to participate in the imaging studies due to severity of dementia

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Alabama at Birmingham,

Jonathan McConathy, MD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

2026-04-01